NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)

RecruitingPhase 1

Sponsor: Merck Sharp & Dohme LLC

Conditions: Healthy

Interventions: MK-8527, Probenecid, Itraconazole

Countries: United States

Researchers are studying a medicine called MK-8527 to learn how it behaves in the body of healthy adults. The goal of this study is to learn about the effect of MK-8527 when it is taken with food or with other medicines. Researchers also want to learn about the safety of MK-8527 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.

Eligibility overview

Sex: ALL

Age: 18 Years to 55 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Be in good health
* Has a body mass index (BMI) between 18 and 32 kg/m\^2, inclusive

Exclusion Criteria:

* Has an estimated glomerular filtration rate (eGFR) ≤90 mL/min/1.73 m\^2
* Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
* Has a history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed)
* Has a history of cancer (malignancy)
* Is taking any medication that contains emtricitabine (FTC) or lamivudine (3TC)

Locations (1)

Daytona Beach, Florida, United States